ScanStation - Faster, Automated Plate Counting for Industry

Hardy Releases Telavancin Susceptibility Disks

Hardy Diagnostics have introduced new Telavancin 30µg, HardyDisk™ used in agar diffusion susceptibility testing methods (Kirby-Bauer).

Hardy Diagnostics is the first company worldwide to achieve 510K clearance to market this susceptibility disk. Telavancin, is a new antibiotic developed by Theravance, a California based biopharmaceutical firm. The FDA has approved telavancin injections (brand name: Vibativ) for once-daily treatment of adults with complicated skin and skin structure infections (cSSSI) caused by susceptible Gram-positive bacteria, including methicillin-resistant and methicillin-susceptible strains of Staphylococcus aureus.


NOTE: This item is from our 'historic' database and may contain information which is not up to date.

Source: Hardy Diagnostics View latest company information

Posted: March 9, 2010
Request Information
[will open your email client]

© 2001 - 2017 Rapid Test Methods Ltd • Please join us on Twitter, Facebook and LinkedIn • RSS Feed